Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil

Abstract

Objective

A combination of 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) is currently recommended for adults with systemic lupus erythematosus (SLE). However, data on the immunogenicity elicited by sequential pneumococcal vaccination in this patient population are scarce. In this study, we compared short-term antibody responses to both PCV13/PPSV23 (≥8-week interval) and PPSV23/PCV13 (≥12-month interval) vaccination strategies in pneumococcal vaccine-naive adults with SLE.

Methods

This longitudinal, open-label, quasi-randomized study was performed in a single-center cohort of adults (18 years or older) with SLE. In both vaccination groups, blood samples were collected immediately before administering the first dose of the pneumococcal vaccine (timepoint T0), 4–6 weeks after the priming dose (T1), and 4–6 weeks after the booster dose (T2). We focused on the 12 shared serotypes between PCV13 and PPSV23, and compared the following immunogenicity outcomes between the groups at T2: anti-pneumococcal antibody geometric mean concentration (ApAb GMC), fold increase in ApAb levels (FI-ApAb), overall seroprotection rate, and overall seroconversion rate. The protective level for each pneumococcal serotype was set at 1.3 μg/mL. We used the multi-analyte immunodetection method to determine serum levels of ApAbs.

Results

Thirty-four patients with SLE were screened between April 2019 and January 2020, and 16 of them (mean age: 39.4 years, 87.5% female, and 100% on immunosuppressants) had evaluable immunogenicity results at T2. The median time elapsed between the pneumococcal vaccinations was 56 days in the PCV13/PPSV23 group (n = 11 patients) and 16 months in the PPSV23/PCV13 group (n = 5 patients). Priming with PCV13 (PCV13/PPSV23 group), as opposed to PPSV23 (PPSV23/PCV13 group), yielded significantly better results regarding FI-ApAb, overall seroconversion rate, and overall seroprotection rate 4–6 weeks after each pneumococcal vaccination. A trend toward augmented ApAb GMC in the patients who received the PCV13/PPSV23 sequence was also observed. No relevant safety issues were identified with sequential pneumococcal vaccination.

Conclusion

The PCV13-priming PPSV23-boost strategy in adults with SLE induced greater antibody responses for most immunogenicity outcomes than those elicited by the PPSV23/PCV13 strategy.

Keywords

Pneumococcal conjugate vaccine pneumococcal polysaccharide vaccine systemic lupus erythematosus immunogenicity antibody response pneumococcal vaccination

Get full access to this article

View all access options for this article.

References

Cervera

Khamashta

Font

, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003; 82: 299–308.

Sartori

De Rezende

RPV

Mendes

, et al. Mortality profile related to the spectrum of systemic connective tissue diseases: a retrospective, population-based, case-control study. Lupus 2019; 28: 1498–1500.

Souza

DCC

Santo

Sato

. Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. J Rheumatol 2012; 39: 496–503.

Centers for Disease Control and Prevention (CDC) . Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2012; 61: 816–819.

Furer

Rondaan

Heijstek

, et al. update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2019; 79: 39–52.

Clutterbuck

Lazarus

L-M

, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205: 1408–1416.

Esposito

Bonanni

Maggi

, et al. Recommended immunization schedules for adults: clinical practice guidelines by the escmid vaccine study group (EVASG), European geriatric medicine society (EUGMS) and the world association for infectious diseases and immunological disorders (WAidid). Hum Vaccin Immunother 2016; 12: 1777–1794.

Grabar

Groh

Bahuaud

, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine 2017; 35: 4877–4885.

Sacre

Goulenok

Bahuaud

, et al. Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE). Ann Rheum Dis 2018; 77: 1540–1542.

10.

Petri

Orbai

A-M

Alarcon

, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

11.

Hochberg

. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

12.

Orange

Ballow

Stiehm

, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the American academy of allergy, asthma & immunology. J Allergy Clin Immunol 2012; 130: S1–S24.

13.

Chan

Molrine

George

, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin’s disease. J Infect Dis 1996; 173: 256–258.

14.

Farmaki

Chini

Mangafas

, et al. Immunogenicity and immunological memory induced by the 13-valent pneumococcal conjugate followed by the 23-valent polysaccharide vaccine in HIV-infected adults. J Infect Dis 2018; 218: 26–34.

15.

De Roux

Schmole-Thoma

Siber

, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015–1023.

16.

O’Brien

Hochman

Goldblatt

. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7: 597–606.

17.

Granhoff

Gupta

Belshe

, et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178: 870–874.

18.

Bonilla

Khan

Ballas

, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136: 1186–1205.

19.

Simell

Auranen

Kayhty

, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012; 11: 841–855.

20.

De Rezende

RPV

Cardoso-Marques

Rodrigues

LAS

, et al. Carriage prevalence, serotype distribution, and antimicrobial susceptibility among pneumococcal isolates recovered from adults with systemic lupus erythematosus. Lupus 2021; 30: 1863–1865.

21.

Kobayashi

Farrar

Gierke

, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: Updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. Morb Mortal Wkly Rep 2022; 71: 109–117.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.29 MB